Sarah Differding
Overview
Explore the profile of Sarah Differding including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
98
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Differding S, Sterpin E, Hermand N, Vanstraelen B, Nuyts S, de Patoul N, et al.
Radiat Oncol
. 2017 Mar;
12(1):59.
PMID: 28335778
Purpose: Validation of dose escalation through FDG-PET dose painting (DP) for oropharyngeal squamous cell carcinoma (SCC) requires randomized clinical trials with large sample size, potentially involving different treatment planning and...
2.
Differding S, Sterpin E, Janssens G, Hanin F, Lee J, Gregoire V
Acta Oncol
. 2015 Jun;
55(2):217-25.
PMID: 26079436
Objective: To develop a methodology for using FDG PET/CT in adaptive dose painting by numbers (DPBN) in head and neck squamous cell carcinoma (HNSCC) patients. Issues related to noise in...
3.
Jouret F, Differding S, Lhommel R, Jadoul M, Lambert M
NDT Plus
. 2015 May;
1(5):371-2.
PMID: 25983941
No abstract available.
4.
Differding S, Hanin F, Gregoire V
Eur J Nucl Med Mol Imaging
. 2015 Jan;
42(4):613-22.
PMID: 25573630
In locally advanced head and neck squamous cell carcinoma (HNSCC), the role of imaging becomes more and more critical in the management process. In this framework, molecular imaging techniques such...
5.
Servagi-Vernat S, Differding S, Sterpin E, Hanin F, Labar D, Bol A, et al.
Acta Oncol
. 2015 Jan;
54(7):1008-16.
PMID: 25562382
Objective: To evaluate from a planning point of view the dose distribution of adaptive radiation dose escalation in head and neck squamous cell carcinoma (HNSCC) using (18)F-Fluoroazomycin arabinoside (FAZA) positron...
6.
Sterpin E, Differding S, Janssens G, Geets X, Gregoire V, Lee J
Acta Oncol
. 2014 Jul;
54(2):253-60.
PMID: 24991892
Background: In the context of dose painting by numbers delivered with intensity-modulated radiotherapy, the robustness of dose distributions against geometric uncertainties can be ensured by robust optimization. As robust optimization...
7.
Servagi-Vernat S, Differding S, Hanin F, Labar D, Bol A, Lee J, et al.
Eur J Nucl Med Mol Imaging
. 2014 Feb;
41(8):1544-52.
PMID: 24570097
Purpose: Hypoxia in head and neck squamous cell carcinoma (HNSCC) is associated with poor prognosis and outcome. (18) F-Fluoroazomycin arabinoside (FAZA) is a positron emission tomography (PET) tracer developed to...